Gossamer Bio GOSS 深 滬
已收盤 05-08 16:00:00 美东时间
0.327
-0.017
-4.86%
華盛通- 最 高0.3493
- 今 開0.34
- 成交量 338.57万股
- 最 低 0.325
- 昨 收 0.3437
- 總市值 7674.57万
- 52周最高 3.87
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 0.32
- 委 比 90.18%
- 總股本 2.35亿
- 歷史最高 27.15
- 量 比 0.89
- 振 幅 7.07%
- 歷史最低 0.32
- 每 手 1
- 風險率 1.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during ...
04-25 05:05
Gossamer Bio Investors File Securities Lawsuit Over Alleged Misstatements About Phase 3 Drug Trial
Gossamer (GOSS) told investors its Phase three PROSERA study was on track, with...
04-23 02:35
Cantor Fitzgerald Downgrades Gossamer Bio to Neutral
Cantor Fitzgerald analyst Olivia Brayer downgrades Gossamer Bio (NASDAQ:GOSS) from Overweight to Neutral.
03-23 17:56
Levi & Korsinsky probes Gossamer Bio statements after PROSERA Phase 3 trial miss
Levi & Korsinsky probes Gossamer Bio statements after PROSERA Phase 3 trial miss Levi & Korsinsky is investigating potential claims on behalf of Gossamer shareholders after the company said its Phase 3 PROSERA study of seralutinib in pulmonary arterial hypertension missed its primary 6-minute walk d
03-19 21:02
Small-Cap healthcare stocks ranked by quant ratings after earnings season
As earnings season winds down, investors are shifting focus to updated quant ratings following the latest wave of corporate results. The scores offer a snapshot of how companies rank across key factor...
03-13 21:55
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
美股大行评级 | 最高582美元！博通获多家机构上调目标价；GENI、Okta、Rigetti Computing、Veeva Systems、Wix.com遭多家机构下调目标价
今日重点评级关注：韦德布什：维持TScan Therapeutics"跑赢大市"评级，目标价从4美元升至5美元；HC Wainwright & Co.：维持莱斯康制药"买入"评级，目标价从4美元升至6美元
03-06 11:58
Oppenheimer Maintains Outperform on Gossamer Bio, Lowers Price Target to $3
Oppenheimer analyst Andreas Argyrides maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and lowers the price target from $12 to $3.
03-06 01:53
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q1
Health care sector has oversold stocks, RSI momentum indicator can help traders predict short term performance. Latest list of oversold players with RSI below 30: GOSS (26.3), BWAY (19.1), DH (20.2).
03-05 19:16
美股牛股 | 获24亿美元电厂合同，BW暴涨近46%；Stevanato Group涨近19%
获24亿美元电厂合同，BW暴涨近46%；业绩超预期！Q4营收同比增长14%，Stevanato Group涨近19%>>
03-05 14:59
